SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 1/07/03 Intermune Inc 8-K:5,7 1/07/03 2:57K Merrill Corp/New/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 22K 2: EX-99.1 Miscellaneous Exhibit HTML 22K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 7, 2003
INTERMUNE, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
94-3296648 |
|
(Commission File No.) |
|
(State of jurisdiction) |
|
(IRS Employer Identification No.) |
3280 Bayshore Boulevard
(Address and registrant’s principal executive offices and zip code)
Registrant’s telephone number, including area code: (415) 466-2200
Item 5. Other Events
On January 6, 2003, InterMune, Inc. issued a press release entitled “ Intermune to Update Investors at the 21st Annual JP Morgan H&Q Healthcare Conference,” announcing that it expects 2002 revenue will be at the upper end of its previously estimated range of $105-110 million, and announcing preliminary survival data from an exploratory three to five month follow-up observational period of its double-blind, placebo-controlled Phase III clinical trial of Actimmune for the treatment of idiopathic pulmonary fibrosis. A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
In February 2003, Intermune will update revenue guidance concerning its products.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits.
Number |
|
Description |
99.1 |
|
Press Release entitled “Intermune to Update Investors at the 21st Annual JP Morgan H&Q Healthcare Conference,” dated January 6, 2003. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
INTERMUNE, INC. |
|
|
|
|
|
Dated: January 7, 2003 |
|
By: |
/s/ STEPHEN N. ROSENFIELD |
|
|
|
Stephen N. Rosenfield |
|
|
|
Senior Vice President of Legal Affairs |
3
EXHIBIT INDEX
Number |
|
Description |
99.1 |
|
Press Release entitled “Intermune to Update Investors at the 21st Annual JP Morgan H&Q Healthcare Conference,” dated January 6, 2003. |
4
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on / For Period End: | 1/7/03 | None on these Dates | ||
1/6/03 | ||||
List all Filings |